Design considerations on the proof of efficacy of functional foods

References

• AbuMweis SS, Jew S, Jones PJ. 2010. Optimizing clinical trial design for assessing the efficacy of functional foods. Nutr Rev. 68 8: 485–499.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. 2000. What do we mean by validating a prognostic model?. Stat Med. 19 4: 453–473.
   PubMed Web of Science ®Google Scholar
• Arai S, Yasuoka A, Abe K. 2008. Functional food science and food for specified health use policy in Japan: state of the art. Curr Opin Lipidol. 19 1: 69–73.
   PubMed Web of Science ®Google Scholar
• . 2008. Neutraceutical and functional food regulationsBagchi D. New York: Elsevier.
   Google Scholar
• Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R. 2010. Evidence-based criteria in the nutritional context. Nutr Rev. 68 8: 478–484.
   PubMed Web of Science ®Google Scholar
• . 2005. The evaluation of surrogate endpoint. In: Burzykowski T, Molenberghs G, Buyse M. editors. . New York: Springer.
   Google Scholar
• Buyse M. 2009. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J. 15 5: 421–425.
   PubMed Web of Science ®Google Scholar
• Buyse M, Molenberghs G. 1998. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 54 3: 1014–1029.
   PubMed Web of Science ®Google Scholar
• Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. 2010. Biomarkers and surrogate end points – the challenge of statistical validation. Nat Rev Clin Oncol. 7 6: 309–317.
   PubMed Web of Science ®Google Scholar
• Chow SC, Lu Q, Tse K. 2007. Statistical analysis for two-stage seamless design with different study endpoints. J Biopharm Stat. 17 6: 1163–1176.
   PubMed Web of Science ®Google Scholar
• Freedman LS, Graubard BI, Schatzkin A. 1992. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 11 2: 167–178.
   PubMed Web of Science ®Google Scholar
• Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. 1995. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 91 8: 2274–2282.
   PubMed Web of Science ®Google Scholar
• Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. 1998. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97 10: 946–952.
   PubMed Web of Science ®Google Scholar
• Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. 2007. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 29 5: 778–794.
   PubMed Web of Science ®Google Scholar
• Heaney RP. 2006. Nutrition, chronic disease, and the problem of proof. Am J Clin Nutr. 84 3: 471–472.
   PubMed Web of Science ®Google Scholar
• Jew S, Vanstone CA, Antoine JM, Jones PJ. 2008. Generic and product-specific health claim processes for functional foods across global jurisdictions. J Nutr. 138 6: 1228S–1236S.
   PubMed Web of Science ®Google Scholar
• Lassere MN. 2008. The biomarker-surrogacy evaluation schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 17 3: 303–340.
   PubMed Web of Science ®Google Scholar
• Li Z, Meredith MP. 2003. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat. 13 4: 777–792.
   PubMedGoogle Scholar
• Lin DY, Zeng D. 2010. On the relative efficiency of using summary statistics versus individual-level data in meta-analysis. Biometrika. 97 2: 321–332.
   PubMed Web of Science ®Google Scholar
• Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 152 1: 56–64.
   PubMedGoogle Scholar
• Prentice RL. 1989. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 8 4: 431–440.
   PubMed Web of Science ®Google Scholar
• Rasnake CM, Trumbo PR, Heinonen TM. 2008. Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. Nutr Rev. 66 2: 76–81.
   PubMed Web of Science ®Google Scholar
• Robins JM, Greenland S. 1992. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 3 2: 143–155.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A. 2009. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev. 22 2: 244–261.
   PubMed Web of Science ®Google Scholar
• Stallard N. 2010. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Stat Med [Epub ahead of print].
   Google Scholar
• Stallard N, Todd S. 2010. Seamless phase II/III designs. Stat Methods Med Res [Epub ahead of print].
   Google Scholar
• Sutton AJ, Higgins JP. 2008. Recent developments in meta-analysis. Stat Med. 27 5: 625–650.
   PubMed Web of Science ®Google Scholar
• Thompson SG, Higgins JP. 2002. How should meta-regression analyses be undertaken and interpreted?. Stat Med. 21 11: 1559–1573.
   PubMed Web of Science ®Google Scholar
• Scientific concepts of functional foods in Europe: Consensus document. 1999. Br J Nutr. 81 Suppl 1: S1–27.
   PubMed Web of Science ®Google Scholar